Daniels A J, Matthews J E, Slepetis R J, Jansen M, Viveros O H, Tadepalli A, Harrington W, Heyer D, Landavazo A, Leban J J, Spaltenstein A
Division of Pharmacology, Burroughs Wellcome Co., Research Triangle Park, NC 27709, USA.
Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9067-71. doi: 10.1073/pnas.92.20.9067.
Neuropeptide Y (NPY) is one of the most abundant peptide transmitters in the mammalian brain. In the periphery it is costored and coreleased with norepinephrine from sympathetic nerve terminals. However, the physiological functions of this peptide remain unclear because of the absence of specific high-affinity receptor antagonists. Three potent NPY receptor antagonists were synthesized and tested for their biological activity in in vitro, ex vivo, and in vivo functional assays. We describe here the effects of these antagonists inhibiting specific radiolabeled NPY binding at Y1 and Y2 receptors and antagonizing the effects of NPY in human erythroleukemia cell intracellular calcium mobilization perfusion pressure in the isolated rat kidney, and mean arterial blood pressure in anesthetized rats.
神经肽Y(NPY)是哺乳动物大脑中含量最为丰富的肽类递质之一。在周围组织中,它与去甲肾上腺素共同储存于交感神经末梢并共同释放。然而,由于缺乏特异性高亲和力受体拮抗剂,该肽的生理功能仍不清楚。合成了三种有效的NPY受体拮抗剂,并在体外、离体和体内功能试验中测试了它们的生物活性。我们在此描述了这些拮抗剂在抑制Y1和Y2受体上特异性放射性标记NPY结合,以及拮抗NPY对人红白血病细胞内钙动员、离体大鼠肾脏灌注压和麻醉大鼠平均动脉血压影响方面的作用。